Clinical study of COAD-B regimen in treatment of patients with relapsed/refractory non-Hodgkin lymphoma.
- Author:
Ming-hui LI
1
;
Yu-fu LI
;
Qing-song YIN
;
Rui-hua MI
;
Lin CHEN
;
Jian-wei DU
;
Xu-dong WEI
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Bleomycin; administration & dosage; Cyclophosphamide; administration & dosage; Cytarabine; administration & dosage; Dexamethasone; administration & dosage; Disease-Free Survival; Humans; Lymphoma, Non-Hodgkin; drug therapy; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Vindesine; administration & dosage
- From: Chinese Journal of Hematology 2013;34(10):857-861
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the efficacy, adverse events and long-term survival of cyclophosphamide, vindesine, cytarabine, dexamethasone and bleomycin (COAD-B) regimen for relapsed and refractory non-Hodgkin lymphoma (NHL).
METHODSEighty six patients diagnosed with relapsed or refractory NHL were included in our study from January 2007 to January 2013. The chemotherapy regimen was COAD-B, the therapeutic efficacy was evaluated every 2 courses. Once the stable disease (SD) or progress of the disease (PD) achieved, the patients would switch to other second-line regimens.
RESULTSThe overall response rate (ORR) was 67.4%, median remission duration was 13 months (3-51 months); 1-,2- and 4-year overall survival (OS) rates were 75.4%, 56.8% and 40.0%, respectively; 1-, 2- and 4-year progression-free survival (PFS) rates were 50.3%, 39.4% and 27.5%, respectively. The main adverse reaction of patients was myelosuppression. The response to chemotherapy and long- term survival of the relapsed patients were significantly better than that of the refractory ones, and the difference had statistical significance.
CONCLUSIONCOAD-B could be the salvage regimen for relapsed and refractory NHL.